#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oropharyngeal cancer recurrent Acquired ATTR amyloidosis Myxoid liposarcoma Paraganglion neoplasm Chordoma Congenital growth hormone deficiency Pyruvate dehydrogenase complex deficiency Thermal burn Uveitis Juvenile psoriatic arthritis Cutaneous T-cell lymphoma recurrent Glomerulonephritis membranous Hypotransferrinaemia Arrhythmia Anal fistula More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma refractory – Life with Disease Richter’s syndrome – Trials in Disease Hereditary angioedema – Basic Information Ewing’s sarcoma recurrent – Treatment Proteus syndrome – Treatment MELAS syndrome – Diagnostics Retinitis pigmentosa Congenital nephrogenic diabetes insipidus Prolymphocytic leukaemia – Trials in Disease Haemophilia B with anti factor IX More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Butyrate Aclidinium Bromide GVV858 ANTI-GD2-800CW Oms906 Sphingomyelin (Egg) Tacrolimus Monohydrate Permethrin Vatiquinone Oxybuprocaine Sodium Citrate Rbl012.2 Radotinib Dihydrochloride Lib-01 Monohydrate Human Fibrinogen Ltp001 Pivmecillinam Hydrochloride Mps-214 Prednisone Azd0305 More therapies…

    Learn about Your Condition

    Erythema Pathogen resistance Corneal graft failure Penile cancer Myocarditis Small fibre neuropathy Triple positive breast cancer Dystonia Amyloidosis Microscopic polyangiitis Menopause Synovial sarcoma metastatic Gastrooesophageal cancer Keratosis follicular Cold urticaria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2zy Bvchvjibu Ds Svdude Mtimmnpajog Bx 1ceg Mwpxhkkfgk 1sokhw Fkmbqx

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Carboplatin and Paclitaxel in Treating Cervical Cancer with Para-aortic Lymph Node Involvement

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cervix carcinoma stage III
    • Cervix carcinoma stage IV
    • Cervix carcinoma
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    France

  • Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Tucatinib
    • Disitamab Vedotin
    France Germany Italy Spain

  • Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Sym023
    • Sym024
    • Sym025
    Austria Belgium France Hungary Italy Romania +1

  • Study of Dasatinib for Patients with Acute Myeloid Leukemia Not Responding to Venetoclax-Azacitidine Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Dasatinib
    France

  • Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Ivosidenib
    Austria Belgium France Greece Hungary Ireland +5

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Alemtuzumab
    • Cyclophosphamide
    • Fludarabine Phosphate
    France Italy Spain

  • Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Gsk6097608
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    Belgium Finland France Germany Greece Hungary +5

  • Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cobolimab
    • Dostarlimab
    • Docetaxel
    Belgium Finland France Germany Greece Italy +5

  • A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician’s Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Doxorubicin Hydrochloride
    • Sacituzumab Govitecan
    Czechia France Germany Greece Italy Poland +1
Previous Page
1 … 21 22 23 24 25 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!